Long-term mortality in patients with severe secondary mitral regurgitation and normal left ventricular ejection fraction: interventional perspective

EuroIntervention 2018;13:1881-1888 published online January 2018. DOI: 10.4244/EIJ-D-17-00561

Amr F. Barakat
Amr F. Barakat1, MD; Mohammad Q. Raza2, MD; Kinjal Banerjee2, MD; Rayji S. Tsutsui2, MD; Amgad Mentias1, MD; Karim Abdur Rehman1, MD; Badal Thakkar2, MD; Sajjad Gul1, MD; Raquib Faruqui2, MD; Amar Krishnaswamy2, MD; Leonardo L. Rodriguez2, MD; Richard Grimm2, DO; Brian Griffin2, MD; Emin Murat Tuzcu2, MD; Samir R. Kapadia2*, MD
1. Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA; 2. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

Aims: Patients with severe secondary mitral regurgitation (MR) and normal ejection fraction are being excluded from clinical trials evaluating transcatheter mitral devices. We sought to e

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

mitral regurgitationmitral valve diseaseother
Interventions for valvular diseaseMitral valve replacement and repair
Read next article
Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies

Latest news